Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 1998

View Archived Issues

Genentech: FY 1997 highlights

CellPro: Q3 1998 highlights

Isis Pharmaceuticals: Q4 and FY 1997 highlights

Ilex Oncology: Q4 and FY 1997 highlights

Guilford: FY 1997 highlights

Substance P antagonists revealed by Boehringer Ingelheim

Tyrosine kinase modulators under development by Yissum, Sugen

Merck describes dopamine D4 receptor ligands with therapeutic potential

A novel NOS inhibitor possibly involved in elevating arterial pressure

Antimetastatic properties of ND-2001, a nojirimycin derivative

Diversa identifies new therapeutic leads on the ocean floor

SKB and WHO join forces to wipe out lymphatic filariasis

Founding of new German biotech company announced

Cubist outlines development plans for daptomycin

Olopatadine still under regulatory review in Japan

Novel VEGF inhibitors in development at Genentech

Small-molecule chemokine receptor antagonists from Teijin

Klinge discovers compounds for asthma with high efficacy and safety

New antiproliferative compounds patented by Warner-Lambert

Tsetse thrombin inhibitor isolated, purified and characterized at Yale

KY-62 evaluated in murine models of candidiasis

New HRT option now available for Canadian women

Centocor to acquire rights to reteplase in U.S., Canada

Selective inhibition of HIV integrase by dicaffeoylquinic and dicaffeoyltartaric acids

SBIR grant goes to OSI for diabetes research

New once-daily antihypertensive combination available in U.S.

Meridian and Duoject to jointly develop innovative drug delivery system

New hope for patients diagnosed with malignant pleural effusions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...